AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17391350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomanic symptoms in patients not in acute bipolar episode
Number of subjects: 253
Study 15483105 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/d) added to Flutamide (62.5 mg/d) and ethinylestradiol-drospirenone for 3 months in study A.
Number of subjects: 73
Study 15483105 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of Metformin after 17 months of therapy in study B.
Number of subjects: 73
Study 15483105 — intervention group
Group type: COMPARATOR
Intervention: Control group in study A (no Metformin).
Number of subjects: 73
Study 15483105 — intervention group
Group type: COMPARATOR
Intervention: Control group in study B (discontinuation of Metformin).
Number of subjects: 73
Study 12429319 — intervention group
Group type: EXPERIMENTAL
Intervention: 5F urethral catheters
Number of subjects: 31
Study 12429319 — intervention group
Group type: COMPARATOR
Intervention: 10F urethral catheters
Number of subjects: 31
Study 10651170 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF patients with DVI during low-workload exercise
Number of subjects: 22
Study 10651170 — intervention group
Group type: COMPARATOR
Intervention: CHF patients without DVI during low-workload exercise
Number of subjects: 22
Study 10651170 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF patients with DVI during peak exercise
Number of subjects: 22
Study 10651170 — intervention group
Group type: COMPARATOR
Intervention: CHF patients without DVI during peak exercise
Number of subjects: 22
Study 7666090 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN‐gamma) 0.2 mg total dose by subcutaneous injection daily for 6 months
Number of subjects: 99
Study 7666090 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 99
Study 7666090 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN‐gamma)
Number of subjects: 99
Study 2669980 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (50 mg GHB/kg/night given 25 mg/kg h.s. and 25 mg/kg 3 hr later)
Number of subjects: 20
Study 2669980 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 20
Study 2669980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1100303 — intervention group
Group type: EXPERIMENTAL
Intervention: Melengestrol
Number of subjects: 0
Study 1100303 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 31812934 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and systematic integration of palliative care (PC) into oncological care
Number of subjects: 186
Study 31812934 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological care alone
Number of subjects: 186
Study 31437272 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based self-care promoting program
Number of subjects: 457
Study 31437272 — intervention group
Group type: COMPARATOR
Intervention: Placebo social calls (Control)
Number of subjects: 457
Study 28590833 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 79
Study 28590833 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 26041862 — intervention group
Group type: EXPERIMENTAL
Intervention: CHK-Alpha (CHKA) immunohistochemistry (IHC)
Number of subjects: 125
Study 26041862 — intervention group
Group type: COMPARATOR
Intervention: Normal prostate tissue
Number of subjects: 125
Study 26041862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67 labelling index (LI) in malignant prostate cores
Number of subjects: 125
Study 26041862 — intervention group
Group type: EXPERIMENTAL
Intervention: CHK intensity stratification
Number of subjects: 125
Study 23747140 — intervention group
Group type: EXPERIMENTAL
Intervention: Older female fallers
Number of subjects: 61
Study 23747140 — intervention group
Group type: COMPARATOR
Intervention: Older female non-fallers
Number of subjects: 61
Study 23747140 — intervention group
Group type: COMPARATOR
Intervention: Younger females
Number of subjects: 61
Study 23747140 — intervention group
Group type: EXPERIMENTAL
Intervention: Older female fallers and non-fallers
Number of subjects: 61
Study 22048097 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional CT
Number of subjects: 85
Study 22048097 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional CT
Number of subjects: 85
Study 19371314 — intervention group
Group type: EXPERIMENTAL
Intervention: Predose meal at 18.00 h
Number of subjects: 36
Study 19371314 — intervention group
Group type: EXPERIMENTAL
Intervention: Predose meal at 21.00 h
Number of subjects: 36
Study 19371314 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdose meal at 22.10 h
Number of subjects: 36
Study 19371314 — intervention group
Group type: COMPARATOR
Intervention: Fasting subjects
Number of subjects: 36
Study 19371314 — intervention group
Group type: EXPERIMENTAL
Intervention: Predose meal at 18.00 h vs fasting subjects
Number of subjects: 36
Study 17010236 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Zn/d
Number of subjects: 387
Study 17010236 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Zn/d
Number of subjects: 387
Study 17010236 — intervention group
Group type: COMPARATOR
Intervention: 0 mg (placebo)
Number of subjects: 387
Study 14564645 — intervention group
Group type: EXPERIMENTAL
Intervention: NUMARIS processing with TE=135 ms
Number of subjects: 28
Study 14564645 — intervention group
Group type: COMPARATOR
Intervention: LCModel processing with TE=135 ms
Number of subjects: 28
Study 14564645 — intervention group
Group type: EXPERIMENTAL
Intervention: NUMARIS processing with TE=10 ms
Number of subjects: 28
Study 14564645 — intervention group
Group type: COMPARATOR
Intervention: LCModel processing with TE=10 ms
Number of subjects: 28
Study 14564645 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation time corrections applied
Number of subjects: 28
Study 14564645 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal intensity ratios from long echo time spectra
Number of subjects: 28
Study 10029243 — intervention group
Group type: EXPERIMENTAL
Intervention: p24-VLP (500 microg) in alum monthly plus zidovudine 200 mg tds
Number of subjects: 24
Study 10029243 — intervention group
Group type: COMPARATOR
Intervention: p24-VLP
Number of subjects: 24
Study 10029243 — intervention group
Group type: COMPARATOR
Intervention: zidovudine
Number of subjects: 24
Study 8681661 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose continuous nebulization (7.5 mg)
Number of subjects: 0
Study 8681661 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose continuous nebulization (2.5 mg)
Number of subjects: 0
Study 8681661 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose intermittent nebulization (2.5 mg)
Number of subjects: 0
Study 8681661 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intermittent nebulization (7.5 mg)
Number of subjects: 0
Study 1653138 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 149
Study 1653138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 6408949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disopyramide phosphate
Number of subjects: 124
Study 6408949 — intervention group
Group type: COMPARATOR
Intervention: Oral quinidine sulfate
Number of subjects: 124
Study 31778522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear ads (N = 52)
Number of subjects: 108
Study 31778522 — intervention group
Group type: COMPARATOR
Intervention: Humor ads (N = 56)
Number of subjects: 108
Study 28386945 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium for oral solution (active treatment)
Number of subjects: 1272
Study 28386945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study 26808852 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval running training
Number of subjects: 8
Study 26808852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 8
Study 24251641 — intervention group
Group type: EXPERIMENTAL
Intervention: rGLP-1 at 5.0 pmol/kg/min
Number of subjects: 95
Study 24251641 — intervention group
Group type: EXPERIMENTAL
Intervention: rGLP-1 at 1.25 pmol/kg/min
Number of subjects: 95
Study 24251641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 22577062 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol with a hydrogoniometer and 2 trained physical therapists
Number of subjects: 48
Study 19387398 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermogenic nutritional supplement
Number of subjects: 28
Study 19387398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18644764 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Promotion strategies (community participation and empowerment, contextualism, intersectorality, multistrategy, equity, and sustainability)
Number of subjects: 0
Study 15860486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous darbepoetin alfa
Number of subjects: 118
Study 15860486 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous darbepoetin alfa
Number of subjects: 118
Study 15860486 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 118
Study 11933033 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based approach for handling missing data
Number of subjects: 0
Study 11933033 — intervention group
Group type: COMPARATOR
Intervention: Standard methods for dealing with missing data
Number of subjects: 0
Study 9764983 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-related cryoglobulinemia
Number of subjects: 211
Study 9764983 — intervention group
Group type: COMPARATOR
Intervention: Chronic hepatitis C
Number of subjects: 211
Study 9764983 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 1 and subtype 1b
Number of subjects: 211
Study 9764983 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-RNA levels
Number of subjects: 211
Study 7835116 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed rhubarb (0.75g/day)
Number of subjects: 333
Study 7835116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 10302610 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment booklet stressing the importance of recognizing information needs and encouraging patients to ask questions
Number of subjects: 67
Study 10302610 — intervention group
Group type: COMPARATOR
Intervention: Placebo education booklet similar in format but not in content
Number of subjects: 67
Study 31724048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 0
Study 31724048 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy
Number of subjects: 0
Study 28359784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 727
Study 28359784 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 727
Study 26158622 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg hepatitis B vaccine at 0, 1 and 3 months (group A)
Number of subjects: 5143
Study 26158622 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg hepatitis B vaccine at 0, 1 and 6 months (group B)
Number of subjects: 5143
Study 26158622 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg hepatitis B vaccine at 0, 1 and 12 months (group C)
Number of subjects: 5143
Study 26158622 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5143
Study 22944555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-low-dose midazolam (KM)
Number of subjects: 61
Study 22944555 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-fentanyl (MF)
Number of subjects: 61
Study 21496064 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg once daily with tamsulosin 0.4 mg
Number of subjects: 2
Study 21496064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg once daily with tamsulosin 0.4 mg
Number of subjects: 2
Study 19656023 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FMSRP)
Number of subjects: 36
Study 19656023 — intervention group
Group type: COMPARATOR
Intervention: Partial-mouth scaling and root planing (PMSRP)
Number of subjects: 36
Study 19656023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FMSRP and PMSRP
Number of subjects: 36
Study 17596049 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified posteromedial release (Group A)
Number of subjects: 86
Study 17596049 — intervention group
Group type: COMPARATOR
Intervention: Modified complete subtalar release (Group B)
Number of subjects: 86
Study 15520363 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (10-50 mg/d)
Number of subjects: 322
Study 15520363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 15520363 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 322
Study 11261519 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (ACA) testing
Number of subjects: 296
Study 11261519 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 296
Study 9204356 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol (Imagopaque 300 mg I/ml)
Number of subjects: 120
Study 9204356 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate (Hexabrix 320 mg I/ml)
Number of subjects: 120
Study 9204356 — intervention group
Group type: EXPERIMENTAL
Intervention: Both iopentol and ioxaglate
Number of subjects: 120
Study 7524945 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (Trasylol; Bayer AG, Leverkusen, Germany) administered intraperitoneally
Number of subjects: 48
Study 7524945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin treatment)
Number of subjects: 48
Study 7524945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 3454656 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps femoris muscle setting (QS) exercises
Number of subjects: 30
Study 3454656 — intervention group
Group type: COMPARATOR
Intervention: Straight-leg-raising (SLR) exercises
Number of subjects: 30
Study 2707520 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 420 mg/day
Number of subjects: 116
Study 2707520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 30703190 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel (70 mg/m2 every 3 weeks for 6 cycles)
Number of subjects: 254
Study 30703190 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 254
Study 30703190 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel
Number of subjects: 254
Study 28892526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg/d for 5 days followed by 15 or 20 mg/d
Number of subjects: 195
Study 28892526 — intervention group
Group type: COMPARATOR
Intervention: Warfarin with a target INR of 2.0-3.0 for 4 weeks
Number of subjects: 195
Study 28892526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 195
Study 28892526 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 195
Study 25482300 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP) and Epstein-Barr virus DNA (EBV DNA) assessment
Number of subjects: 6337
Study 25482300 — intervention group
Group type: EXPERIMENTAL
Intervention: High EBV DNA levels and high hs-CRP level
Number of subjects: 6337
Study 25482300 — intervention group
Group type: EXPERIMENTAL
Intervention: High EBV DNA but low hs-CRP level or high hs-CRP but low EBV DNA
Number of subjects: 6337
Study 25482300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interpretation of EBV DNA with hs-CRP levels
Number of subjects: 6337
Study 23299607 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol, 2000 IU/d
Number of subjects: 146
Study 23299607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 20853132 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic etoposide (50 mg/m2 daily for 21 consecutive days each month) with bevacizumab (10 mg/kg every 2 weeks)
Number of subjects: 23
Study 20853132 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic temozolomide (50 mg/m2 daily) with bevacizumab (10 mg/kg every 2 weeks)
Number of subjects: 23
Study 20001979 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (monotherapy)
Number of subjects: 0
Study 20001979 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (in combination with nifedipine)
Number of subjects: 0
Study 20001979 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (in combination with nifedipine, metformin, and simvastatin)
Number of subjects: 0
Study 17408310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 70
Study 17408310 — intervention group
Group type: COMPARATOR
Intervention: Other QTc interval-prolonging drugs
Number of subjects: 70
Study 17408310 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical studies
Number of subjects: 70
Study 17408310 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological studies
Number of subjects: 70
Study 15012622 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 108
Study 15012622 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 108
Study 15012622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 11710890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 288
Study 11710890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 9272421 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 44
Study 9272421 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg twice daily)
Number of subjects: 44
Study 7949808 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous non-invasive finger artery pressure monitoring (Finapres) during active standing
Number of subjects: 34
Study 7949808 — intervention group
Group type: EXPERIMENTAL
Intervention: Active standing test with continuous beat-to-beat blood pressure recording
Number of subjects: 34
Study 3069521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg/day for 7 days
Number of subjects: 60
Study 3069521 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 300 mg/day for 7 days
Number of subjects: 60
Study 28950757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's chase (RC) technique
Number of subjects: 40
Study 28950757 — intervention group
Group type: COMPARATOR
Intervention: Infusion bag (IB) technique
Number of subjects: 40
Study 27006119 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography (CCTA)
Number of subjects: 1000
Study 27006119 — intervention group
Group type: COMPARATOR
Intervention: Standard evaluation
Number of subjects: 1000
Study 27006119 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 1000
Study 24562444 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (RT)
Number of subjects: 1234
Study 24562444 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (RT)
Number of subjects: 1234
Study 22794219 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortex files (30/.04)
Number of subjects: 16
Study 22794219 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoSequence files (30/.04)
Number of subjects: 16
Study 22794219 — intervention group
Group type: COMPARATOR
Intervention: EndoSequence files (40/.04)
Number of subjects: 16
Study 22794219 — intervention group
Group type: COMPARATOR
Intervention: Vortex files (40/.04)
Number of subjects: 16
Study 21193871 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSH (0.9 mg injections on days 1 and 2)
Number of subjects: 45
Study 21193871 — intervention group
Group type: COMPARATOR
Intervention: Control group (48 matched controls)
Number of subjects: 45
Study 17114205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous disodium pamidronate (APD) given as monthly infusions
Number of subjects: 11
Study 17114205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous disodium pamidronate (APD)
Number of subjects: 11
Study 16269830 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil (n = 40)
Number of subjects: 120
Study 16269830 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil (n = 40)
Number of subjects: 120
Study 16269830 — intervention group
Group type: COMPARATOR
Intervention: No oil control (n = 40)
Number of subjects: 120
Study 14574343 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity (20 min brisk walking)
Number of subjects: 10
Study 14574343 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack (58.5 g chocolate-based)
Number of subjects: 10
Study 14574343 — intervention group
Group type: COMPARATOR
Intervention: Control (sitting, TV-watching)
Number of subjects: 10
Study 10522579 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 min saline-anesthetic interval
Number of subjects: 73
Study 10522579 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min saline-anesthetic interval
Number of subjects: 73
Study 10522579 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min saline-anesthetic interval
Number of subjects: 73
Study 8747265 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Number of subjects: 0
Study 8747265 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft substitutes (allograft, xenograft)
Number of subjects: 0
Study 8747265 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoinductive growth factors
Number of subjects: 0
Study 1718700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 to 120 mg/day, initiated as early as 3 hours after onset of symptoms, for up to 6 months
Number of subjects: 8670
Study 1718700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day, started 7 to 21 days after infarction
Number of subjects: 8670
Study 1718700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8670
Study 1718700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8670
Study 7049112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy using cyclophosphamide, methotrexate, and vincristine for 30 weeks
Number of subjects: 23